PE-22-28
Spadin analog that acts as a natural antidepressant by targeting TREK-1 channels
Clinical Research Score: 2/5 — Evidence is limited to preclinical antidepressant research on spadin analogs; no human trials yet.
Categories: Mental / Cognitive
What is PE-22-28?
PE-22-28 offers a novel approach to mood improvement that works differently from traditional antidepressants. Rather than flooding the brain with serotonin (like SSRIs do), it targets a specific potassium channel that acts as a natural "dimmer switch" on mood. By blocking this channel, it allows the brain's natural mood-elevating pathways to work more effectively.
People describe the effect as a lifting of heaviness. The world looks a little brighter. Motivation returns. Getting out of bed becomes easier. The emotional flatness or persistent low mood begins to ease within days — not the weeks that traditional antidepressants typically require.
What makes PE-22-28 particularly interesting is the speed of onset and the specificity of the mechanism. It's a targeted intervention — one channel, one pathway — rather than the broad neurotransmitter flooding of conventional approaches. For people dealing with persistent low mood, anhedonia, or mild to moderate depressive symptoms, it represents an intriguing alternative approach.
How PE-22-28 works
PE-22-28 blocks the TREK-1 potassium channel — a channel that, when active, dampens neuronal excitability in mood-regulating brain regions. By antagonizing this channel, PE-22-28 increases serotonergic (mood-elevating) activity and promotes neurogenesis in the hippocampus — the brain region critical for emotional regulation and memory. The rapid antidepressant-like effect (seen within days in studies) is attributed to this dual action: immediate neurotransmitter enhancement plus longer-term brain cell growth.
Scientific overview
PE-22-28 is a shorter analog of Spadin, which acts as an antagonist of the TREK-1 potassium channel. TREK-1 has been identified as a target for antidepressant therapy. PE-22-28 blocks this channel, leading to increased serotonergic neurotransmission and neurogenesis in the hippocampus. It has shown rapid antidepressant-like effects in animal models within 4 days of treatment.
Dosing
- Starting dose: 50 mcg per day
- Common dosage range: 50-200 mcg per day
- Administration: Subcutaneous, Nasal
- Half-life: ~2 hours
- Frequency: 1x daily